Sector: MedicalCell Therapeutics, Inc. (NASDAQ: CTIC)
Headlines
- Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
Nov 20, 2009 03:31 AM | CEPH, CTIC
- BrainStorm Stem Cell Therapy Technology Possesses Promising Potential for the Future Treatment of Multiple Sclerosis
Nov 16, 2009 08:14 AM | CTIC
- RidgewaterEquity.com Free Fundamental Sector & Market Research on NITE, TIBX, CTIC, KLAC, BMRN and ETFC
Nov 16, 2009 07:06 AM | CTIC, KLAC, NITE, TIBX
- BrainStorm Chief Medical Advisor Interviewed on Israel Radio Broadcast; States Stem Cell Therapy Treatment Ready For Clinical Trials
Nov 11, 2009 08:01 AM | CTIC
- BrainStorm Stem Cell Therapy Treatment Shown To Be More Effective Than Other Current Potential Stem Cell Treatments
Nov 09, 2009 06:57 AM | CTIC
- Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45%
Nov 05, 2009 01:30 AM | CTIC
- Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 5
Nov 02, 2009 01:30 AM | CTIC
- Cell Therapeutics, Inc.'s (CTI) Presentation at BIO Investor Forum to be Webcast
Oct 29, 2009 01:30 AM | CTIC
- BrainStorm Granted "Outperform" Rating by Murphy Analytics
Oct 27, 2009 08:57 AM | CTIC
- Cell Therapeutics, Inc. (CTI) to Present at 8th Annual BIO Investor Forum
Oct 26, 2009 01:30 AM | CTIC
- Stock on the Move: SUWN -- September 16, 2009
Sep 16, 2009 09:51 AM | CTIC, LXRX, SUWN, THC
- FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone
Aug 24, 2009 01:30 AM | CTIC
- Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
Aug 21, 2009 04:52 PM | CTIC, RODM
- Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
Aug 19, 2009 05:54 PM | CTIC, RODM
- StockPreacher.com Issues Trading Outlook for Cell Therapeutics Inc.
Aug 19, 2009 06:51 AM | CTIC, GILD, TEVA
- Skymark Research Initiates Complimentary Research Coverage On Cell Therapeutics, Inc.
Aug 06, 2009 09:31 AM | CTIC
- Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
Aug 06, 2009 01:30 AM | CTIC
- Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 6
Aug 05, 2009 01:30 AM | CTIC
- OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
Aug 03, 2009 01:31 AM | CTIC
- Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
Jul 29, 2009 01:31 AM | CTIC
- Form 4 CELL THERAPEUTICS INC For: Nov 13 Filed by: MUNDINGER MARY ONEIL (10K)
Nov 13, 2009 08:39 PM
- Form 4 CELL THERAPEUTICS INC For: Nov 13 Filed by: GREGORIAN VARTAN (10K)
Nov 13, 2009 08:34 PM
- Form 4 CELL THERAPEUTICS INC For: Nov 13 Filed by: LOVE RICHARD L (10K)
Nov 13, 2009 08:29 PM
- Form 4 CELL THERAPEUTICS INC For: Nov 13 Filed by: BAUER JOHN H (10K)
Nov 13, 2009 08:19 PM
- Form 4 CELL THERAPEUTICS INC For: Nov 13 Filed by: Telling Fred (10K)
Nov 13, 2009 08:18 PM
- Form 4 CELL THERAPEUTICS INC For: Nov 13 Filed by: NUDELMAN PHILLIP M PHD (10K)
Nov 13, 2009 08:11 PM
- Form 4 CELL THERAPEUTICS INC For: Nov 10 Filed by: Eramian Daniel G (10K)
Nov 12, 2009 08:42 PM
- Form 4 CELL THERAPEUTICS INC For: Nov 10 Filed by: PHILIPS CRAIG (10K)
Nov 12, 2009 08:36 PM
- Form 4 CELL THERAPEUTICS INC For: Nov 10 Filed by: BIANCO JAMES A (10K)
Nov 12, 2009 08:27 PM
- Form 4 CELL THERAPEUTICS INC For: Nov 10 Filed by: BIANCO LOUIS A (10K)
Nov 12, 2009 08:17 PM
Analyst Ratings
Share Performance
|
Period
|
CTIC
|
Compare to S&P
|
| YTD |
604.07 %
|
481.59 %
|
| 4 Weeks |
-9.57 %
|
-10.05 %
|
| 12 Weeks |
-41.67 %
|
-45.27 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -80.00 %
|
|
EPS Growth in Last Year: 96.82 %
|
|
Sales Growth in Last Quarter: 0.00 %
|
|
Sales Growth in Last Quarter: -99.23 %
|
|
